治疗艾滋病毒感染者阿尔茨海默氏病的治疗方法
David B Clifford1, Tammie L S Benzinger2, Jee-Young Han1
1Department of Neurology Washington University St. Louis Missouri USA.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 20, 2026
概括
抗粉样蛋白疗法 (AAT) 显示出治疗艾滋病毒感染者阿尔茨海默病 (AD) 的前景. 早期发现表明AAT是安全的,不会干扰艾滋病毒治疗,为艾滋病毒老龄化人口提供希望.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 老年病的医生 老年病的医生
背景情况:
- 现代人体免疫缺陷病毒 (HIV) 疗法使个人能够活得更久,达到较高的年龄.
- 阿尔茨海默病 (AD) 是一种常见的神经退行性疾病,现在可以用抗粉样蛋白疗法 (AAT) 治疗.
- 艾滋病毒阳性个体被排除在AAT临床试验之外,这使得该人群的安全性和有效性数据未知.
研究的目的:
- 评估AAT的安全性和有效性,在一个艾滋病毒控制良好的个体.
- 评估AAT对正在进行的HIV治疗的影响.
主要方法:
- 一份病例报告详细介绍了艾滋病病毒感染者阿尔茨海默氏病的10年进展情况.
- 使用了全面的临床评估和生物标志物分析.
- 记录了AAT的使用及其对艾滋病毒管理的影响.
主要成果:
- 通过一致的临床和生物标志物证据证实了AD诊断.
- 在没有任何报告的并发症的情况下,AAT被管理.
- 在整个研究期间,艾滋病毒治疗仍然有效.
结论:
- 这一案例为艾滋病毒感染者安全使用AAT提供了初步证据.
- AAT似乎不会对艾滋病毒治疗产生不利影响.
- 这些发现与日益增长的老年艾滋病毒人口相关,这些人可能会发展为AD.
相关概念视频
Retrovirus Life Cycles
43.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42


